Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Battey

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Clinical Chemistry|February 19, 2026
Simultaneous Prenatal cfDNA Screening of Aneuploidy, Recessive Single-Gene Conditions, and Fetomaternal Blood CompatibilityJuexiao Sherry Wang, C J Battey, Kyle Trettin, et al.
Future Oncology (London, England)|June 22, 2026
Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-BreastJulia Foldi, Gregory Hogan, Katherine Johansen Taber, et al.
European Urology|March 1, 2026
KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic ModelChad Tang, Aaron Seo, Alexander D Sherry, et al.
The Lancet. Oncology|September 7, 2025
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trialChad Tang, Alexander D Sherry, Aaron Seo, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Clinical Chemistry|February 19, 2026
Simultaneous Prenatal cfDNA Screening of Aneuploidy, Recessive Single-Gene Conditions, and Fetomaternal Blood CompatibilityJuexiao Sherry Wang, C J Battey, Kyle Trettin, et al.
Future Oncology (London, England)|June 22, 2026
Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-BreastJulia Foldi, Gregory Hogan, Katherine Johansen Taber, et al.
European Urology|March 1, 2026
KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic ModelChad Tang, Aaron Seo, Alexander D Sherry, et al.
The Lancet. Oncology|September 7, 2025
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trialChad Tang, Alexander D Sherry, Aaron Seo, et al.
Pageof 8